AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|AAPL325.69+0.56 (+0.17%) ▲|ABBV260.34+0.35 (+0.13%) ▲|ABT110.89+1.96 (+1.80%) ▲|ACN187.69-0.40 (-0.21%) ▼|ADBE280.82-5.27 (-1.84%) ▼|AMAT438.52-3.33 (-0.75%) ▼|AMD456.62-2.99 (-0.65%) ▼|AMGN441.36+3.24 (+0.74%) ▲|AMT172.50-3.53 (-2.00%) ▼|AMZN255.12+0.20 (+0.08%) ▲|AVGO368.94-0.75 (-0.20%) ▼|AXP329.70+5.51 (+1.70%) ▲|BA208.84+3.18 (+1.55%) ▲|BAC62.64+0.65 (+1.05%) ▲|BKNG199.42+3.73 (+1.91%) ▲|BLK1,111.54-16.56 (-1.47%) ▼|BMY67.71+0.79 (+1.18%) ▲|BNY162.20+1.69 (+1.05%) ▲|BRK-B505.20+2.87 (+0.57%) ▲|C134.30+1.76 (+1.33%) ▲|CAT790.36+11.20 (+1.44%) ▲|CL90.23+0.60 (+0.67%) ▲|CMCSA26.88+0.58 (+2.19%) ▲|COF216.92+5.58 (+2.64%) ▲|COP137.24+1.05 (+0.77%) ▲|COST921.73-18.23 (-1.94%) ▼|CRM258.33+0.22 (+0.09%) ▲|CSCO109.47-0.27 (-0.25%) ▼|CVS97.19-0.41 (-0.42%) ▼|CVX212.49+1.44 (+0.68%) ▲|DE691.98+15.90 (+2.35%) ▲|DHR209.65+2.72 (+1.31%) ▲|DIS108.46+2.24 (+2.11%) ▲|DUK120.57+0.18 (+0.15%) ▲|EMR149.10+1.47 (+1.00%) ▲|FDX317.89-6.99 (-2.15%) ▼|GD365.98-3.43 (-0.93%) ▼|GE330.31-0.78 (-0.24%) ▼|GEV921.89+23.36 (+2.60%) ▲|GILD149.58-0.35 (-0.23%) ▼|GM84.80-0.84 (-0.98%) ▼|GOOG334.31+2.28 (+0.69%) ▲|GOOGL337.76+2.74 (+0.82%) ▲|GS1,005.10+2.54 (+0.25%) ▲|HD317.95-1.82 (-0.57%) ▼|HON205.35-4.63 (-2.21%) ▼|IBM231.78+0.38 (+0.16%) ▲|INTC89.77+0.80 (+0.90%) ▲|INTU343.00-1.94 (-0.56%) ▼|ISRG370.69+1.44 (+0.39%) ▲|JNJ275.44+4.25 (+1.57%) ▲|JPM355.86+0.91 (+0.26%) ▲|KO88.57+0.57 (+0.64%) ▲|LIN488.47+1.71 (+0.35%) ▲|LLY1,164.70+4.70 (+0.41%) ▲|LMT533.83-10.68 (-1.96%) ▼|LOW199.95-0.10 (-0.05%) ▼|LRCX287.31-2.90 (-1.00%) ▼|MA588.70+7.60 (+1.31%) ▲|MCD260.27-0.85 (-0.32%) ▼|MDLZ62.53+0.92 (+1.49%) ▲|MDT92.84+0.80 (+0.87%) ▲|META595.21+16.67 (+2.88%) ▲|MMM168.31-1.93 (-1.13%) ▼|MO69.67+0.10 (+0.14%) ▲|MRK151.69+1.83 (+1.22%) ▲|MS212.29+1.25 (+0.59%) ▲|MSFT496.75-4.27 (-0.85%) ▼|MU952.16+18.72 (+2.00%) ▲|NEE82.93-0.01 (-0.01%) ▼|NFLX82.39+1.58 (+1.95%) ▲|NKE38.25+0.13 (+0.33%) ▲|NOW137.17-5.73 (-4.01%) ▼|NVDA224.69+7.25 (+3.33%) ▲|ORCL146.16+4.84 (+3.42%) ▲|PEP140.42+0.63 (+0.45%) ▲|PFE29.04+0.49 (+1.72%) ▲|PG147.61+1.40 (+0.96%) ▲|PLTR169.24-10.68 (-5.94%) ▼|PM187.20+0.05 (+0.02%) ▲|QCOM169.75+3.14 (+1.88%) ▲|RTX201.54-3.63 (-1.77%) ▼|SBUX107.13+0.98 (+0.92%) ▲|SCHW109.00+0.72 (+0.66%) ▲|SO88.25+0.16 (+0.18%) ▲|SPG209.49-2.38 (-1.12%) ▼|T26.04+0.04 (+0.14%) ▲|TMO608.84+8.34 (+1.39%) ▲|TMUS186.77+4.61 (+2.53%) ▲|TSLA352.94-3.15 (-0.88%) ▼|TXN254.76+1.42 (+0.56%) ▲|UBER76.64+1.40 (+1.86%) ▲|UNH399.82+3.52 (+0.89%) ▲|UNP290.59-0.03 (-0.01%) ▼|UPS103.15+0.49 (+0.48%) ▲|USB62.83+1.62 (+2.65%) ▲|V379.85+7.18 (+1.93%) ▲|VZ50.35+0.05 (+0.11%) ▲|WFC89.66+2.62 (+3.01%) ▲|WMT105.92-0.01 (0.00%) ▼|XOM164.92+0.37 (+0.22%) ▲|
22.6 C
New York
Wednesday, September 2, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 15, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose has received an additional advance of US$2.0M from Hanmi Pharmaceutical Co. as part of a US$8.5M loan facility agreement.

Safest SARMs For Muscle Growth 2025: CrazyBulk Introduces Effective SARMs For Bulking, Cutting and Strength in USA.

Albany, New York, July 15, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of fitness and bodybuilding, achieving optimal muscle growth, fat loss, and recovery without compromising health is paramount. Selective Androgen Receptor Modulators (SARMs) have emerged as a promising alternative to traditional anabolic steroids, offering similar benefits with reduced side effects. However, the safety and legality of SARMs vary, making it crucial for enthusiasts to exercise caution when choosing wisely.

Chalk River Laboratories Becomes First GLP-Certified Laboratory in Canada to Offer Pre-Clinical Radiopharmaceutical Studies

Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory 
Following successful SCC audit, CNL is ready to perform pre-clinical studies for growing radiopharmaceutical industry as GLP-compliant laboratory

Sleep To Live Well Foundation Launches With Groundbreaking Sleep Wellness Report to Tackle National Epidemic and Transform Public Health

SAN JOSE, Calif., July 15, 2025 /PRNewswire/ -- The Sleep To Live Well Foundation issues an urgent warning in its groundbreaking 2025 State of...

Made Scientific and Sentinel BioTherapeutics Announce Strategic Manufacturing Partnership to Advance Ph I/II Allogeneic ePP Encapsulated Cell Therapy Program

PRINCETON, N.J. and HOUSTON, July 15, 2025 /PRNewswire/ -- Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel...

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...

With Help from the California Community Foundation, the YMCA Continues to Provide Relief as it Rebuilds after the Wildfire

LOS ANGELES, July 15, 2025 /PRNewswire/ -- For Jim Kirtley, the executive director of the Palisades-Malibu YMCA, the most painful part of having the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers